Larotrectinib – December 2020

• Brand names:
  • Vitrakvi®
• Pharmaceutical Company:
  • Bayer Australia Ltd
• Condition/Indication: Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions
• Meeting Date: December 2020
• Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1970KB)
• Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 558KB)

Related Public Summary Documents

• Larotrectinib – November 2020